non-small cell lung cancer Articles
-
Improving drug loading efficiency and delivery performance of micro– and nanoparticle preparations through optimising formulation variables
In this report, we briefly introduce our recent studies related to drug delivery systems using biodegradable materials, PLGA, PLA or chitosan to prepare submicroparticles or microparticles for carrying vaccine, protein or small molecule drugs. These preparations were prepared by spray dried or solvent extraction methods. In addition, liposomal formulations containing various lipids and pegylated ...
-
FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
By BOC Sciences
-
Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms
Abstract Background Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical ...
-
What are the Possibilities for ADCs Targeting Trop2?
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the occurrence of many tumors and poor prognosis. It is a very popular ADC research target, second only to HER2. Currently, only Gilead's Trop-2 ADC drug Trodelvy has been approved for ...
By BOC Sciences
-
A new model using artificial intelligence to predict recurrence after surgical resection of stage I-II non-small cell lung cancer.
Abstract Background: Five-year survival for stage I-II lung cancer is quite low even after complete surgical resection. Current guidelines recommend adjuvant treatment only for selected patients with stage II or higher disease. A prediction model that identifies patients at high risk of recurrence who may benefit from adjuvant treatment is greatly needed. Many existing prediction models include ...
-
LAG-3 antibody drug R&D boom
On March 19, Bristol-Myers Squibb (BMS) announced that its dual immunotherapy combination Opdualag had received accelerated marketing approval from the FDA. Opdualag therapy is a fixed-dose combination of Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma, making LAG-3 the third ...
-
Tumor Glycan-Targeted Therapy
Glycosylation is a sophisticated type of post-translational modification that impacts over 50% of cellular proteins and is a critical regulator of many eukaryotic processes. Aberrant glycosylation is a common hallmark of many malignancies and is important at all stages of tumor growth. Glycosylation regulates a range of physiopathological processes, including cell-cell adhesion, cell-matrix ...
-
A "miracle" fruit that can enhance the immune response to tumors
The advent of immune checkpoint inhibitors (ICI) has improved the overall survival of patients with a variety of malignancies. However, the problem of drug resistance to ICI therapy remains a major obstacle limiting its clinical application. The development of drug resistance is associated with multiple factors, including the level of PD-L1 expression in tumor cells, the tumor microenvironment, ...
-
A Combination of Ramucirumab Plus Pembrolizumab Lengthened Survival For Some Lung Cancer Patients
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival ...
-
The Role of MMP-3: Insights into Disease Progression and Therapeutic Potential
The MMP Family Matrix metalloproteinases (MMPs) are a family of enzymes belonging to the metzincin superfamily. There are 23 different types of secreted or membrane-anchored endopeptidases in the human body. MMPs are capable of degrading ECM proteins such as collagen, gelatin, laminin, fibronectin, fibrinogen, elastin, and proteoglycans. They were once considered regulators of the extracellular ...
-
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”. PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) ...
-
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
-
Paclitaxel Injection Market to Grow at Stable CAGR of 12.8% from 2023 to 2032
Global Paclitaxel Injection market document provides actionable industry insights with which sustainable, valuable, and money-spinning business strategies can be created. All the information, facts, and statistics covered in the report lead to actionable ideas, improved decision-making and better-deciding business strategies. With the complete knowledge of business goals and needs to bridge the ...
By insightSLICE
-
CADM: A New Generation of Tumor Suppressor Genes
About Tumor Suppressor Genes A tumor suppressor gene, also known as anti-onco gene, is an essential component of the body's defense against cancer. It usually facilitates apoptosis. With its absence, the human body will be functioning without its “brake” of cell proliferation. Cells are potent to go under abnormal growth processes and finally lead to tumor/cancer. Here are some key ...
-
Bispecific Antibodies and Bispecific Antibody ADCs
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. Bispecific antibody conjugates (BsAb ADCs) are one of the emerging new technologies. The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other ...
By BOC Sciences
-
Based on Antibody Targeted Protein Degradation
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera (AUTEC), Autophagosome Tethering Compound ...
By BOC Sciences
-
descriptors Systems biology approaches to unravel the molecular and genetic architecture of Alzheimer’s disease and related tauopathies
Over time, genetic research have recognized a number of genetic danger variants related to neurodegenerative problems and helped reveal new organic pathways and genes of curiosity. Nevertheless, genetic danger variants generally reside in non-coding areas and should regulate distant genes reasonably than the closest gene, in addition to a gene’s interplay companions in organic networks. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you